Int J Heart Fail.
2024 Apr;6(2):47-55. 10.36628/ijhf.2023.0058.
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF
- Affiliations
-
- 1Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy
- 2Cardiology, San Raffaele Cassino Hospital, Cassino, Italy
- 3St George's University Medical School of London, London, UK
- 4IRCCS San Raffaele, Rome, Italy
- KMID: 2555727
- DOI: http://doi.org/10.36628/ijhf.2023.0058
Abstract
- Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies. This review covers concepts on precision medicine approaches for HFmrEF and HFpEF. Areas discussed include HFmrEF mechanisms, anti-inflammatory and antifibrotic treatments for obesity-related HFpEF, If inhibition for HFpEF with atrial fibrillation, and mineralocorticoid receptor antagonism for chronic kidney disease-HFpEF. Incorporating precision phenotyping and matched interventions in HFmrEF and HFpEF trials will further advance therapy compared to blanket approaches.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of heart failure with a preserved ejection fraction
- Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty
- Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges
- Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
- Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology
